Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation.
OBJECTIVE
This study was undertaken to determine maternal and perinatal outcomes after expectant management of severe preeclampsia between 24 and 33 weeks' gestation.


METHODS
A prospective observational study of 239 women with severe preeclamptic and undelivered after antenatal steroid prophylaxis was performed. Pregnancy prolongation and maternal and perinatal morbidities were analyzed according to the gestational age at time of expectant management: 24 to 28, 29 to 31, and 32 to 33 weeks. Statistical analysis was performed by Student t test and chi(2) test.


RESULTS
The days of pregnancy prolongation were significantly higher among those managed at less than 29 weeks (6) compared with the other groups (4). There were 13 perinatal deaths: 12 in those managed at less than 29 weeks and 1 in those managed at 29 to 31 weeks. Neonatal morbidities were significantly higher among those managed at less than 29 weeks compared with the other groups. There were no instances of maternal death or eclampsia. Maternal morbidities were similar among the groups.


CONCLUSIONS
Expectant management of severe preeclampsia at 24 to 33 weeks in a tertiary care center is associated with good perinatal outcome with a minimal risk for the mother.
CHI Créteil, Creteil, France. bhaddad@chicreteil.fr
Bassam
B
Haddad
Stéphanie
S
Deis
François
F
Goffinet
Bernard J
BJ
Paniel
Dominique
D
Cabrol
Baha M
BM
Siba
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002585:Cesarean Section; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D005323:Fetal Monitoring; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D008423:Maternal Age; D008428:Maternal Mortality / Q000639:trends*; D008875:Middle Aged; D011225:Pre-Eclampsia / Q000175:diagnosis* / Q000628:therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome; D018566:Pregnancy, High-Risk; D011273:Pregnancy, Prolonged; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D013256:Steroids / Q000627:therapeutic use
D000959:Antihypertensive Agents; D013256:Steroids